1. Optum expands coverage for Deep TMS for adolescents with MDD. 2. This policy affects over 48 million covered lives. 3. Growing recognition of Deep TMS in mental health care is highlighted. 4. Approximately 5 million adolescents in the U.S. face major depression. 5. BrasinsWay's Deep TMS shows proven clinical efficacy and potential market growth.
FAQ
Why Bullish?
The expansion of coverage indicates growing acceptance of Deep TMS, which could lead to increased revenue. History shows similar events have led to stock price increases.
How important is it?
The article highlights significant regulatory changes that directly impact BWAY’s market position and growth potential in a key demographic.
Why Long Term?
The policy expansion will likely facilitate long-term revenue growth as more patients access treatment. Comparable expansions in the past for other companies contributed to sustained market performance.
BrainsWay Expands Deep TMS Coverage for Adolescent Depression
BURLINGTON, Mass. and JERUSALEM, December 22, 2025 (GLOBE NEWSWIRE) — BrainsWay Ltd. (NASDAQ & TASE: BWAY), a leader in advanced noninvasive brain stimulation technologies, has announced a significant expansion in coverage for its Deep TMS™ therapy. Optum Behavioral Health, part of UnitedHealth Group and serving over 48 million covered lives, will now provide coverage for adolescents aged 15 and older diagnosed with major depressive disorder (MDD).
Implications of Policy Expansion
This policy update represents a critical advancement in mental health treatment options for younger patients grappling with MDD. Hadar Levy, CEO of BrainsWay, remarked, “Optum's policy expansion marks an important step forward in expanding access to a more effective, clinically proven, and non-drug treatment option for young people affected by MDD.” This initiative reflects the company’s commitment to innovation and early intervention in mental health care.
Growing Acceptance of Deep TMS Among Insurers
Optum's decision aligns with a broader trend in the insurance sector. Other leading insurers, including:
- Evernorth Health Services
- CVS/Aetna
- Medi-Cal
- PacificSource Health Plans
- TRICARE
- Health Care Service Corporation
- Highmark
- Regence
- Florida Blue
- Blue Cross Blue Shield of Michigan
- Blue Cross Blue Shield of North Carolina
These insurers collectively cover around 180 million lives, signaling a growing acceptance of Deep TMS as a vital element of modern mental health care.
The Adolescent Depression Epidemic
Approximately 5 million adolescents aged 15–21 in the United States are estimated to experience major depression, a situation that poses a significant public health challenge. Symptoms of depression can severely affect developmental milestones, academic performance, family relationships, and overall emotional growth. Furthermore, for many adolescents, existing treatment options remain inadequate, especially for those who do not respond well to medication.
Deep TMS as a Treatment Option
BrainsWay's Deep TMS, which is FDA cleared as an adjunct therapy for adolescents with depression, has shown meaningful response and remission rates in clinical studies. This neurostimulation treatment offers renewed hope during a critical developmental stage. The company's proprietary H-coil technology and continued clinical research support its leadership in the mental health field.
About BrainsWay
Founded in 2003, BrainsWay is a global pioneer in advanced noninvasive neurostimulation therapies for mental health disorders. The company has achieved three FDA-clearances backed by clinical studies, including indications for major depressive disorder, obsessive-compulsive disorder, and smoking addiction. BrainsWay is dedicated to enhancing global awareness and access to its Deep TMS technology.
Forward-Looking Statements
This article contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These statements may involve risks and uncertainties, which could cause actual results to differ significantly from projected outcomes. The company disclaims any obligation to update these statements in light of new information or future developments.
For more information on BrainsWay and updates on their technologies, please visit www.brainsway.com.